Literature DB >> 24011939

Psychiatric disorders and symptoms severity in patients with adenotonsillar hypertrophy before and after adenotonsillectomy.

Erkan Soylu1, Nusret Soylu, Yavuz Selim Yıldırım, Öner Sakallıoğlu, Cahit Polat, Israfil Orhan.   

Abstract

OBJECTIVE: The objective of this study was to compare the frequency of psychiatric disorders and the severity of psychiatric symptoms in patients with adenotonsillar hypertrophy with a healthy control group and investigate the potential improvement after adenotonsillectomy.
MATERIALS AND METHODS: The study group consisted of 40 patients with adenotonsillar hypertrophy and a control group consisted of 35 healthy volunteers without adenotonsillar hypertrophy. A routine ear nose throat (ENT) examination, flexible nasopharyngoscopy and tympanometry were carried out. The same procedures were applied to the control group. The parents of all the participants were required to fill out the Early Childhood Inventory-4 form, the Strengths and Difficulties Questionnaire and a personal information form. At postoperative month six, the patients were re-examined, and their parents were required to fill out the same forms.
RESULTS: Attention deficit hyperactivity disorders and sleep disorders determined with the Early Childhood Inventory-4 were more common in the patients with adenotonsillar hypertrophy than in the control group. There was a significant decrease in the rates of both types of disorders at postoperative month six. The total psychiatric symptom severity was higher in the patients with adenotonsillar hypertrophy and the following were more frequent: cases of attention deficit hyperactivity disorder, oppositional defiant disorder, symptom severity of anxiety disorders and sleep disorders determined with the Early Childhood Inventory-4, as well as emotional problems, attention deficit hyperactivity disorder problems, behavioural problems and peer problems determined with the Strengths and Difficulties Questionnaire parent-report form. There was a statistically significant decrease in all the other symptoms at postoperative month six, except for the severity of oppositional defiant disorder symptoms determined with the Early Childhood Inventory-4 and behavioural problems determined with the Strengths and Difficulties Questionnaire parent-report form. There were no differences in the severity of psychiatric disorders or symptoms between the adenotonsillar hypertrophy group and the control group at postoperative month six.
CONCLUSION: Adenotonsillar hypertrophy is associated with psychiatric disorders and symptoms. Adenotonsillectomy ameliorated the symptoms and the severity of these disorders in most cases.
Copyright © 2013 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Adenotonsillar hypertrophy; Adenotonsillectomy; Attention deficit hyperactivity disorders; Psychiatric disorder; Psychiatric symptoms; Sleep disordered breathing

Mesh:

Year:  2013        PMID: 24011939     DOI: 10.1016/j.ijporl.2013.08.020

Source DB:  PubMed          Journal:  Int J Pediatr Otorhinolaryngol        ISSN: 0165-5876            Impact factor:   1.675


  4 in total

Review 1.  Associations of sleep disturbance with ADHD: implications for treatment.

Authors:  Allan Hvolby
Journal:  Atten Defic Hyperact Disord       Date:  2014-08-17

2.  Does Adenotonsillectomy alter Symptoms of Attention Deficit Hyperactivity Disorder in Children?

Authors:  Reza Fallah; Aliasghar Arabi Mianroodi; Mahin Eslami; Narges Khanjani
Journal:  Iran J Otorhinolaryngol       Date:  2020-11

3.  Family, personal, parental correlates and behavior disturbances in school-aged boys with attention-deficit/hyperactivity disorder (ADHD): a cross-sectional study.

Authors:  Yuan-Chang Hsu; Chih-Tsai Chen; Hao-Jan Yang; Pesus Chou
Journal:  Child Adolesc Psychiatry Ment Health       Date:  2022-04-19       Impact factor: 7.494

4.  Medical and Psychiatric Comorbidities in Korean Children and Adolescents with Attention-Deficit/Hyperactivity Disorder.

Authors:  Kee Jeong Park; Jung Sun Lee; Hyo-Won Kim
Journal:  Psychiatry Investig       Date:  2017-11-07       Impact factor: 2.505

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.